The present disclosure relates to antibodies including human antibodies and antigen- binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The disclosure also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The disclosure also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The disclosure also relates to isolated heavy and light chain immunoglobulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present disclosure also relates to methods of making human anti- MAdCAM antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The disclosure also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies. The disclosure also relates to transgenic animals or plants comprising nuclpeic acid molecules of the disclosure.La presente descripción se refiere a anticuerpos que incluyen anticuerpos humanos y porciones de unión al antígeno de estos que se unen específicamente a MAdCAM, preferentemente MAdCAM humana y que funcionan para inhibir MAdCAM. La descripción se refiere además a anticuerpos anti-MAdCAM humanos y porciones de unión al antígeno de estos. La descripción se refiere además a anticuerpos que son anticuerpos quiméricos, biespecíficos, derivatizados, de cadena sencilla o porciones de proteínas de fusión. La descripción se refiere además a inmunoglobulinas de cadenas pesadas y ligeras aisladas derivadas de anticuerpos anti-MAdCAM humanos y moléculas de ácido nucleico que codifican tales inmunoglobulinas. La presente descripción se refiere además a métodos para producir anticuerpos anti-MAdCAM humanos, composiciones que comprenden estos anticuerpos y métodos de uso
